Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
The closing price of Enlivex Therapeutics Ltd (NASDAQ: ENLV) was $1.08 for the day, up 2.86% from the previous closing price of $1.05. In other words, the price has increased by $2.86 from its previous closing price. On the day, 0.63 million shares were traded. ENLV stock price reached its highest trading level at $1.115 during the session, while it also had its lowest trading level at $1.05.
Ratios:
Our analysis of ENLV’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 7.20 and its Current Ratio is at 7.20. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, H.C. Wainwright on March 02, 2021, Reiterated its Buy rating but revised its target price to $33 from $22 previously.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ENLV now has a Market Capitalization of 25757894 and an Enterprise Value of 5709930.
Stock Price History:
The Beta on a monthly basis for ENLV is 0.82, which has changed by -0.13599998 over the last 52 weeks, in comparison to a change of 0.14460516 over the same period for the S&P500. Over the past 52 weeks, ENLV has reached a high of $2.10, while it has fallen to a 52-week low of $0.81. The 50-Day Moving Average of the stock is -14.05%, while the 200-Day Moving Average is calculated to be -3.58%.
Shares Statistics:
ENLV traded an average of 490.43K shares per day over the past three months and 2166070 shares per day over the past ten days. A total of 23.85M shares are outstanding, with a floating share count of 22.66M. Insiders hold about 5.00% of the company’s shares, while institutions hold 11.52% stake in the company. Shares short for ENLV as of 1753920000 were 196537 with a Short Ratio of 0.40, compared to 1751241600 on 194139. Therefore, it implies a Short% of Shares Outstanding of 196537 and a Short% of Float of 0.86.
Earnings Estimates
A comprehensive evaluation of Enlivex Therapeutics Ltd (ENLV) is underway, with the input of 1.0 analysts contributing to its current rating.The consensus estimate for the next quarter is -$0.15, with high estimates of -$0.15 and low estimates of -$0.15.
Analysts are recommending an EPS of between -$0.58 and -$0.58 for the fiscal current year, implying an average EPS of -$0.58. EPS for the following year is -$0.59, with 1.0 analysts recommending between -$0.59 and -$0.59.
